Close Menu

CMS

The third-party consulting group used for the analysis recommended using a survey to set Medicare payment rates to reduce the reporting burden on laboratories.

News items for the in vitro diagnostics industry for the week of March 29, 2021.

The company has previously offered its liquid biopsy tests through an LDT model but sees the timing and the clinical niche as right for a regulatory bid in CSF testing.

The test uses prognostic markers to group women based on their risk of 10-year recurrence of ductal carcinoma in situ.

The guidance says private health plans can't use medical screening criteria to deny coverage for COVID-19 diagnostic tests for asymptomatic patients.

The final decision includes some changes, most notably removing requirements for guideline inclusion, but retains its technical performance benchmarks.

The firm will scale US-based testing capacity for its LiquidHallmark liquid biopsy assay, which uses amplicon-based technology to detect cancer-related mutations.

Amid increasing spending on genetic testing, there are more opportunities for bad actors to implement interstate, fraudulent billing schemes, according to OIG.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

The companies will work with labs to improve payors' understanding of the costs of performing PD-L1 testing and the value it provides to patient care.

Pages